Drug Profile
Acetylcysteine lysinate - Laboratoires SMB
Alternative Names: L-Lysine-N-acetyl-L-cysteinate; N-acetylcysteine lysinate; NacystelynLatest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Galephar; Laboratoires SMB
- Class Antiacnes; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acne vulgaris; Chronic obstructive pulmonary disease
- Discontinued Cystic fibrosis
Most Recent Events
- 01 Sep 2022 LABORATOIRES SMB completes a phase II trial in Acne vulgaris (In adolescents, In adults, Combination therapy) in Bulgaria (PO) (EudraCT2020-005270-10)
- 18 Aug 2021 Phase-II clinical trials in Acne vulgaris (In adolescents, In adults, Combination therapy) in Bulgaria (PO) (EudraCT2020-005270-10)
- 20 Aug 2020 Phase-II clinical trials in Chronic obstructive pulmonary disease in Belgium (Inhalation) before August 2020 (EudraCT2019-001160-29)